The Role of Antidepressants in the Management of Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis
CNS Drugs,  Evidence Based Medicine  Clinical Article

Hauser W et al. – The tricyclic antidepressant (TCA) amitriptyline and the serotonin noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) duloxetine and milnacipran are first–line options for the treatment of fibromyalgia syndrome (FMS) patients. Physicians and patients should be realistic about the potential benefits of antidepressants in FMS. A small number of patients experience a substantial symptom relief with no or minor adverse effects. However, a remarkable number of patients dropout of therapy because of intolerable adverse effects or experience only a small relief of symptoms, which does not outweigh the adverse effects.

Methods
  • Studies with a randomized controlled trial (RCT) design comparing any types of antidepressants with pharmacological placebo or head–to–head comparisons of different types of antidepressants in FMS patients were included.
  • RCTs in which antidepressants were combined with any other defined treatment or antidepressants were tested against anything but drug placebo were excluded.
  • Patients diagnosed with FMS according to predefined criteria of any age were included.
  • To be included, studies had to assess at least one key domain of FMS (pain, sleep, fatigue, health–related quality of life [HRQOL]) as outcomes of efficacy and report total treatment discontinuation rates and/or dropout rates due to adverse events as outcomes for harms.
  • Data were extracted according to protocols of previous systematic reviews on antidepressants in FMS.
  • Methodology quality was assessed by the van Tulder score.
  • Standardized mean differences (SMD) were calculated for continuous outcomes by means and standard deviations and relative risks (RR) for 30% pain reduction and total dropout rate for comparisons of antidepressants with placebo.
  • Examination of the combined results was performed by a random effects model.
  • The authors used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD.
  • Heterogeneity was tested by the I2 statistic.
  • Thirty–five studies were included in the meta–analysis.

Results
  • The SMDs of serotonin noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) on pain, sleep, fatigue, depression and HRQOL were significant.
  • Based on Cohen's categories, the effect size on pain was small and the ones on sleep, fatigue, depression and HRQOL were not substantial.
  • 1481/3528 (42.0%) patients with SNRIs and 737/2304 (32.0%) patients with placebo reported a 30% pain reduction (number needed to treat [NNT] 10.0; 95% CI 8.00, 13.4; I2=4%).
  • The RR of dropouts due to adverse events was 1.83 (95% CI 1.53, 2.18; I2=33%).
  • The SMDs of selective serotonin reuptake inhibitors (SSRIs) on pain, sleep, depression and HRQOL were significant.
  • Based on Cohen's categories, the effect sizes on pain, depression and HRQOL were small and the one on sleep not substantial.
  • 72/198 (36.4%) patients with SSRIs and 40/194 (20.6%) patients with placebo reported a 30% pain reduction (NNT 6.3; 95% CI 4.1, 14.1).
  • The RR of dropouts due to adverse events was 1.60 (95% CI 0.84, 3.04; I2=0%).
  • The SMDs of tricyclic antidepressants (TCAs) on pain, sleep, fatigue and HRQOL were significant.
  • Based on Cohen's categories, the effect sizes on pain and sleep were moderate and the ones on fatigue and HRQOL were small.
  • 140/290 (48.3%) patients with TCAs and 70/252 (27.8%) patients with placebo reported a 30% pain reduction (NNT 4.9; 95% CI 3.5, 8.0).
  • The RR of dropouts due to adverse events was 0.84 (95% CI 0.46, 1.52; I2=0%).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: A nationwide register-based cohort study in Denmark CNS Drugs, June 18, 2014    Clinical Article

2 Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis FOCUS, June 16, 2014    Evidence Based Medicine

3 Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials Psychosomatic Medicine, March 20, 2014    Evidence Based Medicine    Review Article    Clinical Article

4 Re-evaluating the role of antidepressants in cancer-related depression: A systematic review and meta-analysis General Hospital Psychiatry, June 4, 2014    Evidence Based Medicine

5 Does pharmacological treatment of ADHD in adults enhance parenting performance?: Results of a double-blind randomized trial CNS Drugs, June 12, 2014    Clinical Article

6 Association between C-reactive protein and depression: modulated by gender and mediated by body weight Psychiatry Research, June 19, 2014    Clinical Article

7 A comparison of the effects of hatha yoga and resistance exercise on mental health and well-being in sedentary adults: A pilot study Complementary Therapies in Medicine, June 20, 2014    Clinical Article

8 Attachment anxiety is related to epstein-barr virus latency Brain, Behavior, and Immunity, June 23, 2014    Clinical Article

9 Pretreatment brain states identify likely nonresponse to standard treatments for depression Biological Psychiatry, May 23, 2014    Clinical Article

10 Physical diseases among persons with obsessive compulsive symptoms and disorder: A general population study Social Psychiatry and Psychiatric Epidemiology, June 13, 2014    Clinical Article

11 Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy CNS Spectrums, May 30, 2014    Clinical Article

12 Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study BMJ, June 24, 2014    Evidence Based Medicine    Clinical Article

13 A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan war veterans American Journal of Psychiatry, June 9, 2014    Clinical Article

14 A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- A meta-analysis of 31 studies Full Text BMC Psychiatry, May 20, 2014    Free full text    Evidence Based Medicine    Clinical Article

15 Predicting autism diagnosis by 7 years of age using parent report of infant social communication skills Journal of Paediatrics and Child Health, June 10, 2014    Clinical Article

16 Risk of myocardial infarction and stroke in bipolar disorder: A systematic review and exploratory meta-analysis Acta Psychiatrica Scandinavica, June 2, 2014    Evidence Based Medicine    Review Article

17 Myofascial pain in war veterans with post-traumatic stress disorder Journal of Musculoskeletal Pain , June 11, 2014    Clinical Article

18 Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: A randomized double blind placebo controlled clinical trial Journal of Affective Disorders, June 9, 2014    Clinical Article

19 Elevated fetal steroidogenic activity in autism Full Text Molecular Psychiatry, June 25, 2014    Free full text    Clinical Article

20 Eveningness and insomnia: independent risk factors of nonremission in major depressive disorder SLEEP, May 7, 2014    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close